ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer

Peltola, Katriina J., Bono, Petri, Jones, Robert Hugh ORCID: https://orcid.org/0000-0003-3576-9496, Vjaters, Egils, Nykänen, Pirjo, Vuorela, Annamari, Oksala, Riikka, Pohjanjousi, Pasi, Mustonen, Mika V.J., Fizazi, Karim and Massard, Christopher 2020. ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer. European Urology Focus 6 (1) , pp. 63-70. 10.1016/j.euf.2018.08.022

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Background Most prostate cancer patients develop castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment. CRPC growth is mediated mostly by androgen receptor signalling driven by primary androgens synthesised largely by the CYP17A1 enzyme. Objective To evaluate the safety profile and dose-limiting toxicities of ODM-204. Design, setting, and participants In this open, uncontrolled, nonrandomised, multicentre, tolerability and pharmacokinetic first-in-man phase I dose escalation study, patients with metastatic CRPC were randomised to receive ODM-204 in sequential cohorts of five dose levels (ie, 50, 100, 200, 300, and 500 mg twice daily) concomitantly with prednisone. Intervention ODM-204, a novel, orally administered, investigational, nonsteroidal dual inhibitor of CYP17A1 and androgen receptor. Outcome measurements and statistical analysis ODM-204 plasma concentrations, serum testosterone, and prostate-specific antigen (PSA) levels were evaluated and imaging of lesions was performed. Results and limitations Of the 23 patients enrolled into the study, 60.9% experienced mild adverse effects considered to be related to the study treatment, which were fatigue, increased/decreased appetite, nausea, asthenia, diarrhoea, and weight decrease. ODM-204 area under the curve (AUC0–12) values increased dose dependently until the 300 mg dose. The AUC was lower on day 8 after repeated dosing compared with day 1 from the 200 mg dose upwards. Decreases in testosterone levels were seen with ODM-204 treatment confirming androgen deprivation. Of the patients, 13% also demonstrated a >50% decrease in PSA at week 12 and continued ODM-204 treatment for over a year. Conclusions ODM-204 was well tolerated up to the highest evaluated dose. There were decreases in both testosterone and PSA levels, suggesting preliminary antitumour activity in the treatment of CRPC. The pharmacokinetic properties of the molecule, however, prevent further development. Patient summary This study looked at the safety of ODM-204, a novel dual inhibitor of CYP17A1 and the androgen receptor, in castration-resistant prostate cancer patients. ODM-204 treatment was found to be well tolerated, and it also reduced both serum testosterone and prostate-specific antigen levels, but the properties of the molecule prevent further development.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine European Cancer Stem Cell Research Institute (ECSCRI)
Publisher:	Elsevier
ISSN:	2405-4569
Date of First Compliant Deposit:	8 March 2019
Date of Acceptance:	27 August 2018
Last Modified:	15 Nov 2024 23:15
URI:	https://orca.cardiff.ac.uk/id/eprint/120397

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item